ArticleVirology journal2021
Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions.
Article in Virology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 70 citations in OpenAlex.
- Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile.Science advances · 2021Trial
- Structural mimics of SARS-CoV-2.Infection · 2026Review
- Applications of Pseudoviruses Bearing Glycoproteins of SARS-CoV-2 and Influenza Virus.Advances in experimental medicine and biology · 2026Review
- Review
- Development of pseudotyped VSV-SARS-CoV-2 spike variants for the assessment of neutralizing antibodies.Bioanalysis · 2024Article
- Presence of neutralizing SARS-CoV-2 antibodies in asymptomatic population of N'Djamena, Chad.Immunity, inflammation and disease · 2024Article
- An Integrated Research-Clinical BSL-2 Platform for a Live SARS-CoV-2 Neutralization Assay.Viruses · 2023Article
- Research progress in methods for detecting neutralizing antibodies against SARS-CoV-2.Analytical biochemistry · 2023Review
- Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives.Chemical science · 2023Review
- A pseudovirus-based platform to measure neutralizing antibodies in Mexico using SARS-CoV-2 as proof-of-concept.Scientific reports · 2022Article
- Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.Viruses · 2022Article
- Article
- Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies.Microbiological research · 2022Review
- Severe Acute Respiratory Syndrome Coronavirus 2 Serology Testing - A Laboratory Primer.Clinics in laboratory medicine · 2022Review
- SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes.Microorganisms · 2021Article
- Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review.Innovation (Cambridge (Mass.)) · 2021Review
- Article
- Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy.Reviews in medical virology · 2021Review
- Construction and applications of SARS-CoV-2 pseudoviruses: a mini review.International journal of biological sciences · 2021Review
- Advances in understanding the formation and fate of B-cell memory in response to immunization or infection.Oxford open immunology · 2021Review
Corrections and comments
- Update of
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundVirus neutralization by antibodies is an important prognostic factor in many viral diseases. To easily and rapidly measure titers of neutralizing antibodies in serum or plasma, we developed pseudovirion particles composed of the spike glycoprotein of SARS-CoV-2 incorporated onto murine leukemia virus capsids and a modified minimal murine leukemia virus genome encoding firefly luciferase. This assay design is intended for use in laboratories with biocontainment level 2 and therefore circumvents the need for the biocontainment level 3 that would be required for replication-competent SARS-CoV-2 virus. To validate the pseudovirion assay, we set up comparisons with other available antibody tests including those from Abbott, Euroimmun and Siemens, using archived, known samples.
results11 out of 12 SARS-CoV-2-infected patient serum samples showed neutralizing activity against SARS-CoV-2-spike pseudotyped MLV viruses, with neutralizing titers-50 (NT
conclusionsSARS-CoV-2 spike/MLV pseudovirions provide a practical means of assessing neutralizing activity of antibodies in serum or plasma from infected patients under laboratory conditions consistent with biocontainment level 2. This assay offers promise also in evaluating immunogenicity of spike glycoprotein-based candidate vaccines in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.